Latest 8-K filings

Fiserv announced second quarter 2026 financial results showing a 4% decrease in GAAP revenue and a 37% decrease in GAAP EPS compared to the prior year, with adjusted metrics also showing declines.

Immunovant announced its fiscal first quarter 2026 financial results, highlighting on-track clinical development for IMVT-1402 across six indications and a robust cash balance.

Aclaris Therapeutics announced its second quarter 2026 financial results, highlighting positive Phase 1a trial data for ATI-052 and reaffirming timelines for key clinical readouts, with a cash runway extending through 2028.

Versant Media Group announced its second quarter 2026 financial results, reporting $1.64 billion in revenue and $211 million in net income, while also raising its full-year outlook.

Roivant Sciences announced first-quarter 2026 financial results, highlighting strong progress in its drug development pipeline, including upcoming data readouts and a potential September 2026 launch for brepocitinib.

Xeris Biopharma announced robust second quarter 2026 financial results, featuring a 34% year-over-year increase in net product revenue driven by Recorlev, and tightened its full-year revenue guidance.

Sionna Therapeutics reported its Q2 2026 financial results, highlighting that its key clinical trials for SION-719 and SION-451 are on track for topline data this summer, and maintaining a strong cash position expected to fund operations into 2028.

Ironwood Pharmaceuticals reported strong second quarter 2026 results, exceeding expectations and leading to an increase in full-year financial guidance for LINZESS net sales, total revenue, and adjusted EBITDA.

Tarsus Pharmaceuticals announced a $125 million private placement equity financing, including common stock and pre-funded warrants, to fund clinical development and commercial activities.

CareCloud announced its second quarter 2026 financial results, reporting a 16% increase in revenue to $31.9 million and its ninth consecutive quarter of positive GAAP net income, while reaffirming full-year guidance.

Bausch + Lomb Corporation announced updates to its Board of Directors and reaffirmed its full-year 2026 financial guidance, following a strong second quarter with 9% revenue growth.

REGENXBIO announced robust second-quarter 2026 financial results and operational highlights, including significant capital raises and positive clinical trial updates across its gene therapy pipeline.

Scholar Rock reported Q2 2026 results, highlighting progress on its apitegromab BLA with a potential FDA approval by September 30, 2026, and initiating a Phase 2 trial for FSHD.

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million, bolstering its eye care pipeline with gildeuretinol for Stargardt disease.

Sharon AI Holdings Inc. reported Q2 2026 results, highlighting a major strategic collaboration with NVIDIA, significant capacity expansion, and a substantial increase in Total Contract Value.

Teleflex announced its second quarter 2026 financial results, highlighting strong performance in Vascular and Surgical businesses, but revised revenue outlook due to integration delays in the Vascular Intervention business.

Vistance Networks announced its second quarter 2026 financial results, reporting a net sales decrease of 1.4% year-over-year to $319.6 million, alongside a significant drop in Core non-GAAP adjusted EBITDA.

Datadog reported a strong second quarter for 2026, with revenue climbing 36% year-over-year to $1.12 billion, driven by robust growth in larger customers and the successful launch of AI-powered products.

Commerce.com, Inc. announced second quarter 2026 financial results, reporting a return to GAAP net income and growth in Annual Recurring Revenue (ARR).

OpenText announced its fourth quarter and full fiscal year 2026 financial results, showcasing robust growth in cloud revenues and improved profitability.

Zoetis reported flat Q2 2026 revenue of $2.5 billion and revised its full-year guidance downwards, citing a pressured Companion Animal market and increased competition.

Cullinan Therapeutics announced its second quarter 2026 financial results, highlighting progress in its T cell engager programs for autoimmune diseases and cancer, alongside a robust cash position extending runway into 2029.

Vistance Networks announced a one-time special cash distribution of $5.00 per share, funded by the sale of its Ruckus Networks business, with a payment date of August 27, 2026.

Smith Douglas Homes announced second quarter 2026 results, showing a 25% increase in home closings and a 32% rise in net new home orders, but a substantial drop in pretax income due to inventory impairment charges.

Shift4 Payments announced robust Q2 2026 financial results, showcasing significant year-over-year growth in gross revenue and Adjusted EBITDA, alongside continued international expansion.

Core Natural Resources announced robust second quarter 2026 financial and operational results, highlighted by strong net income, adjusted EBITDA, and significant capital returns to stockholders.

Bentley Systems announced robust second-quarter 2026 financial results, showcasing significant year-over-year growth in total revenues, subscriptions revenues, and Annualized Recurring Revenues (ARR).

Resolute Holdings Management, Inc. reported a significant increase in net loss per share to $(1.53) for the second quarter of 2026, compared to $(0.07) in the prior year, while Non-GAAP Fee-Related Earnings per share rose to $0.69.

Iovance Biotherapeutics announced record second-quarter 2026 revenue of $99.3 million, a 66% year-over-year increase, alongside significant clinical and regulatory advancements for its TIL therapies.

Tecnoglass Holdings Inc. announced record second quarter 2026 revenues of $295.3 million, a 15.6% increase year-over-year, driven by strong performance in both residential and commercial segments, despite facing higher raw material costs and tariffs.